title: Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases.
abstract: Components of the human immunoglobulin A1 (IgA1) hinge governing sensitivity to cleavage by bacterial IgA1 proteases were investigated. Recombinant antibodies with distinct hinge mutations were constructed from a hybrid comprised of human IgA2 bearing half of the human IgA1 hinge region. This hybrid antibody and all the mutant antibodies derived from it were resistant to cleavage by the IgA1 proteases from Streptococcus oralis and Streptococcus mitis biovar 1 strains but were cleaved to various degrees by those of Streptococcus pneumoniae, some Streptococcus sanguis strains, and the type 1 and 2 IgA1 proteases of Haemophilus influenzae, Neisseria meningitidis, and Neisseria gonorrhoeae. Remarkably, those proteases that cleave a Pro-Ser peptide bond in the wild-type IgA1 hinge were able to cleave mutant antibodies lacking a Pro-Ser peptide bond in the hinge, and those that cleave a Pro-Thr peptide bond in the wild-type IgA1 hinge were able to cleave mutant antibodies devoid of a Pro-Thr peptide bond in the hinge. Thus, the enzymes can cleave alternatives to their preferred postproline peptide bond when such a bond is unavailable. Peptide sequence analysis of a representative antibody digestion product confirmed this conclusion. The presence of a cleavable peptide bond near the CH2 end of the hinge appeared to result in greater cleavage than if the scissile bond was at the CH1 end of the hinge. Proline-to-serine substitution at residue 230 in a hinge containing potentially cleavable Pro-Ser and Pro-Thr peptide bonds increased the resistance of the antibody to cleavage by many IgA1 proteases.
authors.affiliation: Division of Pathology and Neuroscience, University of Dundee Medical School, Ninewells Hospital, Dundee, United Kingdom. j.m.woof@dundee.ac.uk.
authors.forename: Bernard W
authors.initials: BW
authors.lastname: Senior
authors.forename: Jenny M
authors.initials: JM
authors.lastname: Woof
mesh_terms: D000595:Amino Acid Sequence; D001419:Bacteria / Q000201:enzymology*; D005803:Genes, Immunoglobulin; D006193:Haemophilus influenzae / Q000201:enzymology; D006801:Humans; D007070:Immunoglobulin A / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D009154:Mutation; D009344:Neisseria gonorrhoeae / Q000201:enzymology; D009345:Neisseria meningitidis / Q000201:enzymology; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism*; D013291:Streptococcus / Q000145:classification / Q000201:enzymology
chemical_list: D007070:Immunoglobulin A; D011994:Recombinant Proteins; D012697:Serine Endopeptidases; C021433:IgA-specific serine endopeptidase
references.citation: Infect Immun. 2000 Feb;68(2):463-9
references.pmid: 10639405
references.citation: Infect Immun. 1998 Dec;66(12):5620-9
references.pmid: 9826334
references.citation: J Infect Dis. 2001 Oct 1;184(7):922-5
references.pmid: 11550129
references.citation: J Biol Chem. 2002 Apr 5;277(14):11987-94
references.pmid: 11815614
references.citation: Infect Immun. 2003 Mar;71(3):1462-9
references.pmid: 12595464
references.citation: Infect Immun. 2003 May;71(5):2563-70
references.pmid: 12704129
references.citation: J Clin Invest. 1974 Dec;54(6):1295-300
references.pmid: 4436434
references.citation: Science. 1975 Dec 12;190(4219):1103-5
references.pmid: 810892
references.citation: N Engl J Med. 1978 Nov 2;299(18):973-6
references.pmid: 99655
references.citation: J Infect Dis. 1979 Jan;139(1):89-92
references.pmid: 108339
references.citation: J Immunol. 1980 Jun;124(6):2596-600
references.pmid: 6768797
references.citation: J Exp Med. 1980 Nov 1;152(5):1442-7
references.pmid: 6776228
references.citation: J Infect Dis. 1982 Aug;146(2):266-74
references.pmid: 6809843
references.citation: Annu Rev Microbiol. 1983;37:603-22
references.pmid: 6416146
references.citation: Mol Immunol. 1983 Sep;20(9):1039-49
references.pmid: 6417473
references.citation: Mol Immunol. 1983 Sep;20(9):1051-8
references.pmid: 6358864
references.citation: EMBO J. 1984 Jul;3(7):1595-601
references.pmid: 6430698
references.citation: Infect Immun. 1990 May;58(5):1186-94
references.pmid: 2182537
references.citation: Infect Immun. 1991 May;59(5):1818-22
references.pmid: 1902197
references.citation: FEMS Microbiol Lett. 1992 Apr 15;71(2):199-203
references.pmid: 1601289
references.citation: Biotechnology (N Y). 1992 Jul;10(7):799-804
references.pmid: 1368270
references.citation: J Infect Dis. 1992 Dec;166(6):1316-21
references.pmid: 1431249
references.citation: Infect Immun. 1984 Sep;45(3):550-7
references.pmid: 6147309
references.citation: Nature. 1987 Jan 29-Feb 4;325(6103):458-62
references.pmid: 3027577
references.citation: J Med Microbiol. 1987 Sep;24(2):175-80
references.pmid: 3309325
references.citation: Gene. 1989 Apr 15;77(1):61-8
references.pmid: 2744488
references.citation: Infect Immun. 1989 Oct;57(10):3097-105
references.pmid: 2506130
references.citation: J Immunol. 1993 Nov 1;151(9):4743-52
references.pmid: 8409433
references.citation: Mol Immunol. 1993 Oct;30(14):1243-8
references.pmid: 8413325
references.citation: Infect Immun. 1996 Mar;64(3):933-7
references.pmid: 8641803
references.citation: APMIS. 1996 May;104(5):321-38
references.pmid: 8703438
references.citation: Infect Immun. 1996 Oct;64(10):3957-66
references.pmid: 8926055
references.citation: FEBS Lett. 1997 Mar 17;405(1):86-90
references.pmid: 9094430
references.citation: Mol Microbiol. 1997 Jun;24(5):1083-94
references.pmid: 9220014
references.citation: Infect Immun. 1998 Jan;66(1):181-90
references.pmid: 9423856
references.citation: FEBS Lett. 2000 Apr 28;472(2-3):287-92
references.pmid: 10788628